Exploring mutation specific beta blocker pharmacology of the pathogenic late sodium channel current from patient-specific pluripotent stem cell myocytes derived from long QT syndrome mutation carriers

References

• Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957;54(1):59–68.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation. 2006;113(6):783–790.
   PubMed Web of Science ®Google Scholar
• Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: are all beta-blockers equivalent? Heart Rhythm. 2017;14(1):e41–e44.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Ackerman MJ, Wilde AAM. Channelopathies as Causes of Sudden Cardiac Death. Card Electrophysiol Clin. 2017;9(4):537–549.
   PubMedGoogle Scholar
• Wilde AAM, Amin AS. Clinical spectrum of SCN5A mutations: long QT syndrome, Brugada syndrome, and cardiomyopathy. JACC Clin Electrophysiol. 2018;4(5):569–579.
   PubMedGoogle Scholar
• Bohnen MS, Peng G, Robey SH, et al. Molecular pathophysiology of congenital long QT syndrome. Physiol Rev. 2017;97(1):89–134.
   PubMed Web of Science ®Google Scholar
• Keating M. Linkage analysis and long QT syndrome. Using genetics to study cardiovascular disease. [Review]. Circulation. 1992;85(6):1973–1986. J1 - Circ.
   PubMed Web of Science ®Google Scholar
• Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12(1):17–23.
   PubMed Web of Science ®Google Scholar
• Jiang C, Atkinson D, Towbin JA, et al. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity [see comments]. Nat Genet. 1994;8(2):141–147.
   PubMed Web of Science ®Google Scholar
• Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80(5):795–803.
   PubMed Web of Science ®Google Scholar
• Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62(4):760–781.
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(7083):463–469.
   PubMed Web of Science ®Google Scholar
• Wang Q, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80(5):805–811.
   PubMed Web of Science ®Google Scholar
• Moreno JD, Clancy CE. Pathophysiology of the cardiac late Na current and its potential as a drug target. J Mol Cell Cardiol. 2012;52(3):608–619.
   PubMed Web of Science ®Google Scholar
• Makielski JC. Late sodium current: a mechanism for angina, heart failure, and arrhythmia. Trends Cardiovasc Med. 2016;26(2):115–122.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103(1):89–95.
   PubMed Web of Science ®Google Scholar
• Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–2867.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Kass RS. Long QT syndrome: from channels to cardiac arrhythmias. J Clin Invest. 2005;115(8):2018–2024.
   PubMed Web of Science ®Google Scholar
• Papa A, Kushner J, Marx SO. Adrenergic regulation of calcium channels in the heart. Annu Rev Physiol. 2022;84(1):285–306.
   PubMedGoogle Scholar
• Barsheshet A, Goldenberg I, O-Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome. Circulation. 2012;125(16):1988–1996.
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Thottathil P, Lopes CM, et al. Trigger-specific ion-channel mechanisms, risk factors, and response to therapy in type 1 long QT syndrome. Heart Rhythm. 2012;9(1):49–56.
   PubMed Web of Science ®Google Scholar
• Mullally J, Goldenberg I, Moss AJ, et al. Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations. Heart Rhythm. 2013;10(3):378–382.
   PubMed Web of Science ®Google Scholar
• Priori SG, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292(11):1341–1344.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101(6):616–623.
   PubMed Web of Science ®Google Scholar
• Wei J, Wang DW, Alings M, et al. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na + channel. Circulation. 1999;99(24):3165–3171.
   PubMed Web of Science ®Google Scholar
• Deschenes I, and Baroudi G, Berthet M, et al. Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. Cardiovasc Res. 2000;46(1):55–65.
   PubMed Web of Science ®Google Scholar
• Makita N, Behr E, Shimizu W, et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest. 2008;118(6):2219–2229.
   PubMed Web of Science ®Google Scholar
• Bennett PB, Yazawa K, Makita N, et al. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376(6542):683–685.
   PubMed Web of Science ®Google Scholar
• An RH, Bangalore R, Rosero SZ, et al. Lidocaine block of LQT-3 mutant human Na + channels. Circ Res. 1996;79(1):103–108.
   PubMed Web of Science ®Google Scholar
• Calvillo L, Spazzolini C, Vullo E, et al. Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients. Heart Rhythm. 2014;11(1):126–132.
   PubMed Web of Science ®Google Scholar
• Fabritz L, Franz MR, Carmeliet E, et al. To the Editor–Propranolol, a beta-adrenoreceptor blocker, prevents arrhythmias also by its sodium channel blocking effect. Heart Rhythm. 2014;11(3):e1.
   PubMed Web of Science ®Google Scholar
• Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome: an International multicenter study. Circulation. 2016;134(12):872–882.
   PubMed Web of Science ®Google Scholar
• Ahn J, Kim HJ, Choi J-I, et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: a meta-analysis. PLoS One. 2017;12(10):e0185680.
   PubMed Web of Science ®Google Scholar
• Terrenoire C, Wang K, Chan Tung KW, et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol. 2013;141(1):61–72.
   PubMed Web of Science ®Google Scholar
• Yazawa M, Hsueh B, Jia X, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature. 2011;471(7337):230–234.
   PubMed Web of Science ®Google Scholar
• Bankston JR, Kass RS. Molecular determinants of local anesthetic action of beta-blocking drugs: implications for therapeutic management of long QT syndrome variant 3. J Mol Cell Cardiol. 2010;48(1):246–253.
   PubMed Web of Science ®Google Scholar
• Roden DM, Wood AJJ. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–1022.
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci. 2005;26(3):119–124.
   PubMed Web of Science ®Google Scholar
• Mizusawa Y, Horie M, Wilde AA. Genetic and clinical advances in congenital long QT syndrome. Circ J. 2014;78(12):2827–2833.
   PubMed Web of Science ®Google Scholar
• Clancy CE, Tateyama M, Kass RS. Insights into the molecular mechanisms of bradycardia-triggered arrhythmias in long QT-3 syndrome. J Clin Invest. 2002;110(9):1251–1262.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ. Management of long QT syndrome. Nat Clin Pract Cardiovasc Med. 2005;2(7):346–351.
   PubMedGoogle Scholar
• Hirose S, Makiyama T, Melgari D, et al. Propranolol attenuates late sodium current in a long QT syndrome type 3-human induced pluripotent stem cell model. Front Cell Dev Biol. 2020;8:761.
   PubMed Web of Science ®Google Scholar
• Nies AS, Shand DG. Clinical pharmacology of propranolol. Circulation. 1975;52(1):6–15.
   PubMed Web of Science ®Google Scholar
• Salehifar E, Ebrahim S, Shiran M-R, et al. Pharmacokinetic parameters and over-responsiveness of Iranian population to propranolol. Adv Pharm Bull. 2017;7(2):195–202.
   PubMed Web of Science ®Google Scholar
• Wojcicki J, Jaroszynska M, Droździk M, et al. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Biopharm Drug Dispos. 2003;24(5):211–218.
   PubMed Web of Science ®Google Scholar
• Cales P, Grasset D, Ravaud A, et al. Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol. 1989;27(6):763–770.
   PubMed Web of Science ®Google Scholar
• Duff HJ, Roden DM, Brorson L, et al. Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. J Am Coll Cardiol. 1983;2(6):1134–1140.
   PubMed Web of Science ®Google Scholar
• Ahrens-Nicklas RC, Clancy CE, and Christini DJ. Re-evaluating the efficacy of {beta}-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling. In Cardiovasc Res. 2009. Vol. 82(3). p. 439-47.
   Google Scholar